Clinician’s Guide to Prevention and Treatment of Osteoporosis
Open accessThe DOI matches its Crossref record; 101 of the 102 references it cites were found in a registry or an index; 41 of the 169 sources its claims cite were checked for support.
Abstract
The Clinician's Guide to Prevention and Treatment of Osteoporosis was developed by an expert committee of the National Osteoporosis Foundation (NOF) in collaboration with a multispecialty council of medical experts in the field of bone health convened by NOF. Readers are urged to consult current prescribing information on any drug, device, or procedure discussed in this publication.
Overview
CoChat Summary
TL;DR
This NOF Clinician’s Guide provides recommendations for prevention, risk assessment, diagnosis, and treatment of osteoporosis in postmenopausal women and men age 50 and older, including BMD testing, vertebral imaging, FRAX-based intervention thresholds, and FDA-approved pharmacotherapy. It emphasizes that osteoporosis is common, underdiagnosed, and treatable, with treatment thresholds and drug-specific fracture risk reductions summarized.
Key findings
- Osteoporosis affects more than 9.9 million Americans, with an additional 43.1 million having low bone density; about 1 in 2 Caucasian women and approximately 1 in 5 men will experience an osteoporosis-related fracture. Annually, 2 million fractures are attributed to osteoporosis, causing more than 432,000 hospital admissions, almost 2.5 million medical office visits, and about 180,000 nursing home admissions; costs are expected to rise to $25.3 billion by 2025. Only 23% of women age 67 or older who have an osteoporosis-related fracture receive either a BMD test or a prescription for osteoporosis drug in the 6 months after fracture.
- Pharmacologic treatment is recommended for hip or vertebral fracture, T-score ≤−2.5 at the femoral neck, total hip, or lumbar spine, or low bone mass (T-score between −1.0 and −2.5) with a 10-year hip fracture probability ≥3% or a 10-year major osteoporosis-related fracture probability ≥20% by US-adapted FRAX.
- Universal recommendations include calcium intake of 1000 mg/day for men 50–70 and 1200 mg/day for women 51 and older and men 71 and older; vitamin D 800–1000 IU/day for adults age 50 and older; regular weight-bearing and muscle-strengthening exercise; fall risk assessment and modification; smoking cessation; and avoidance of excessive alcohol.
- Selected drug efficacy data: alendronate reduces spine and hip fractures by about 50% over 3 years; zoledronic acid reduces vertebral fractures by 70%, hip fractures by 41%, and nonvertebral fractures by 25% over 3 years; denosumab reduces vertebral fractures by about 68%, hip fractures by about 40%, and nonvertebral fractures by about 20% over 3 years; teriparatide reduces vertebral fractures by about 65% and nonvertebral fragility fractures by about 53%; raloxifene reduces vertebral fractures by about 30% with prior vertebral fracture and about 55% without; calcitonin reduces vertebral fracture occurrence by about 30% but has not been shown to reduce nonvertebral fractures; ibandronate reduces vertebral fractures by about 50% but nonvertebral fracture reduction has not been documented.
Methods
- Design: guideline developed by an expert committee of the National Osteoporosis Foundation in collaboration with a multispecialty council of medical experts in bone health; recommendations apply to postmenopausal women and men age 50 and older.
- Data or sample: no primary study sample; the Guide synthesizes evidence including NHANES III prevalence estimates, the Women’s Health Initiative, FDA prescribing information, WHO FRAX, and cost-effectiveness analyses.
- Main analysis: expert consensus and evidence synthesis; absolute risk thresholds for pharmacologic intervention were guided by a cost-effectiveness analysis; diagnostic assessment uses central DXA, vertebral imaging, and US-adapted WHO FRAX.
Limitations
- Stated: FRAX underestimates fracture risk in patients with recent fractures, multiple osteoporosis-related fractures, and increased fall risk; it has not been validated for lumbar spine BMD, is not intended for younger adults or children, and has not been validated in patients currently or previously treated with osteoporosis pharmacotherapy.
- Stated: evidence of efficacy beyond 5 years is limited; rare safety concerns such as osteonecrosis of the jaw and atypical femur fractures become more common beyond 5 years; there are relatively few data confirming fracture risk reductions with pharmacotherapy in patients selected by low bone mass plus FRAX thresholds; fracture data are limited in glucocorticoid-induced osteoporosis and in men; and in the absence of head-to-head trials, direct comparisons of risk reduction among drugs should be avoided.
- Evident: the text does not report a systematic search strategy or formal evidence-grading system; the therapeutic thresholds are described as clinical guidance only and “not rules,” requiring individualized clinical judgment.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
![Fig. 1 Micrographs of normal vs. osteoporotic bone [9], from Dempster et al., with permission of The American Society for Bone and Mineral Research [9]](https://figures.cochat.ai/paper-figures/d609b75c87444980afa9b5aebc701061/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-1.jpg)
![Fig. 2 Pathogenesis of osteoporosis-related fractures, from Cooper and Melton, with modification [10]](https://figures.cochat.ai/paper-figures/ff3ff2f3f4b84a5bbd00a8cc79080d62/clinicians-guide-to-prevention-and-treatment-of-osteoporosis-figure-2.jpg)

Verification
Claims the paper makes
29 Valid · 18 Not valid · 68 Not checked · 17 Own results and interpretations
Some cited sources support this claim and some don’t — read each source’s verdict below.
In the paper
“Raloxifene is also indicated for the reduction in risk of invasive breast cancer in postmenopausal women with osteoporosis [83–86].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Estrogen agonist/antagonist (formerly known as SERMs): Raloxifene
What the sources say
- Not checked — no full text of the sourcecites [83] Cauley JA Norton L Lippman ME Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation Breast Cancer Res Treat 2001 65 2 125 134 10.1023/A:1006478317173 11261828 source
- Disputedcites [84] Martino S Cauley JA Barrett-Connor E CORE Investigators Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene J Natl Cancer Inst 2004 96 23 1751 1761 10.1093/jnci/djh319 15572757 sourceExperimental — accuracy not yet measured
The introduction (p. 1) says raloxifene was approved for preventing and treating postmenopausal osteoporosis, while tamoxifen was the only agent approved in the United States to reduce breast cancer incidence. Although the CORE results (p. 5) show reduced invasive breast cancer incidence with raloxifene, they do not support the claim that breast cancer risk reduction was an approved indication. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
- Not checked — no full text of the sourcecites [85] Vogel VG Costantino JP Wickerham DL National Surgical Adjuvent Breast and Bowel Project (NSABP) Effects of tamoxifen vs. raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial JAMA 2006 295 23 2727 2741 10.1001/jama.295.23.joc60074 16754727 source
- Partly supportedcites [86] Barrett-Connor E Mosca L Collins P Raloxifene Use for The Heart (RUTH) Trial Investigators Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women N Engl J Med 2006 355 2 125 137 10.1056/NEJMoa062462 16837676 sourceExperimental — accuracy not yet measured
The Primary Outcomes (p. 5) report that raloxifene reduced invasive breast cancer in the RUTH trial, and the introductory text (p. 2) reports a similar finding from MORE, an osteoporosis-treatment trial. The paper does not state that breast-cancer risk reduction is an approved indication for postmenopausal women with osteoporosis; RUTH enrolled women with or at increased risk for coronary heart disease. (LLM, conf=0.84)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Ibandronate reduces the incidence of vertebral fractures by about 50 % over 3 years, but reduction in risk of nonvertebral fracture with ibandronate has not been documented [50].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Pharmacologic therapy > Bisphosphonates
What the sources say
- Disputedcites [50] Chesnut CH 3rd Skag A Christiansen C Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis J Bone Miner Res 2004 19 18 1241 1249 10.1359/JBMR.040325 15231010 sourceExperimental — accuracy not yet measured
The Clinical osteoporotic nonvertebral fractures section reports a statistically significant 69% reduction with daily ibandronate in women with a baseline femoral-neck BMD T score below −3.0. The Discussion cautions that this was a post hoc analysis and says there was no significant reduction in the overall population, but the unqualified claim that a reduction has not been documented overlooks the reported subgroup finding. Page numbers were not provided in the supplied passages. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“A vertebral fracture is consistent with a diagnosis of osteoporosis, even in the absence of a bone density diagnosis, and is an indication for pharmacologic treatment with osteoporosis medication to reduce subsequent fracture risk [18, 21].”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Vertebral imaging
What the sources say
- Not checked — no full text of the sourcecites [18] Kanis JA Melton LJ 3rd Christiansen C Johnston CC Khaltaev N The diagnosis of osteoporosis J Bone Miner Res 1994 9 8 1137 1141 10.1002/jbmr.5650090802 7976495 source
- Supportedcites [21] Melton LJ Chrischilles EA Cooper C Lane AW Riggs BL How many women have osteoporosis? J Bone Miner Res 2005 20 5 886 892 10.1359/jbmr.2005.20.5.886 15931736 source
The conclusion (OSTEOPENIA, p. 6) distinguishes osteoporosis assessed by bone mineral measurements from established osteoporosis assessed by the occurrence of specific fractures. The introduction (p. 2) identifies vertebral fractures among the principal osteoporosis-related fractures, supporting the stated diagnosis without a bone-density diagnosis. (LLM, conf=0.91)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Help determine adequacy of patient compliance and persistence with osteoporosis therapy”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The review’s “Compliance and persistence” section describes a model in which a bone turnover marker result could lead to a conclusion that compliance or treatment response was inadequate, but notes that the model did not include test-accuracy data. “Measures of adherence” says that a marker-identified non-response could reflect non-compliance or non-persistence, among several other causes. The source therefore supports markers as a possible clue, not as a way to determine the adequacy of both compliance and persistence. (LLM, conf=0.83)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Predict magnitude of BMD increases with FDA-approved therapies”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Biochemical markers of bone turnover
What the sources say
- Partly supportedcites [25] Burch J Rice S Yang H Neilson A Stirk L Francis R Holloway P Selby P Craig D Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups Health Technol Assess (Winchester, England) 2014 18 11 1 206 PMC4781229 24534414 sourceExperimental — accuracy not yet measured
The Clinical Effectiveness and Cost-Effectiveness Evidence section reports correlations between changes in bone turnover markers and BMD, including a statistically significant but weak correlation during teriparatide treatment. It also says not all correlations were significant and cautions that their usefulness varies by population. The review does not establish that markers predict the magnitude of BMD increases across FDA-approved therapies generally. (LLM, conf=0.84)
plainstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
87 more claims · 25 with their cited sources checked
Create a free account to see all 132 claims and to verify the 18 references still open.
- Probably not a substantial claim. 26
- It may state two separate claims as one. 25
- The quote only partly states this claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“this equated to a health care cost of $1088”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Previous studies31,46,47,48 in emergency department patients have identified primarily benefits, including reductions in health care costs, medical retirement, and depressive symptoms.”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“yielding an uptake of 89.9%”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
In the citing paper
“this issue was addressed by instead performing a thorough cost accounting from 2 specific exemplar interventions.30,31”
From Accuracy requirements for cost-effective suicide risk prediction among primary care patients in the US (2021) · cites this paper as [31]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Diagnostic assessment
“Screening BMD and vertebral imaging recommendations for men are outlined in Table 8.”
§ Clinician’s Guide to Prevention and Treatment of Osteoporosis > Approach to the diagnosis and management of osteoporosis > Additional bone densitometry technologies
“Table: Table 8 Additional bone densitometry technologies”
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Neer, R. M., Arnaud, C. D., Zanchetta, J. R., Prince, R., Gaich, G. A., Reginster, J.-Y., Hodsman, A. B., Eriksen, E. F., Ish-Shalom, S., Genant, H. K., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105103441904 · Cited by 4,602
Incidence and Economic Burden of Osteoporosis-Related Fractures in the United States, 2005–2025
Burge, R., Dawson-Hughes, B., Solomon, D. H., Wong, J. B., King, A., & Tosteson, A. (2007) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.061113 · Cited by 4,026
Interventions for preventing falls in older people living in the community
Gillespie, L. D., Robertson, M. C., Gillespie, W. J., Sherrington, C., Gates, S., Clemson, L., & Lamb, S. E. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007146.pub3 · Cited by 3,966
Professor Kanis, J. A., Melton, L. J., Christiansen, C., Johnston, C. C., & Khaltaev, N. (1994) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.5650090802 · Cited by 3,849
Black, D. M., Cummings, S. R., Karpf, D. B., Cauley, J. A., Thompson, D. E., Nevitt, M. C., Bauer, D. C., Genant, H. K., Haskell, W. L., Marcus, R., et al. (1996) · The Lancet · doi:10.1016/s0140-6736(96)07088-2 · Cited by 3,846
Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis
Cummings, S. R., Martin, J. S., McClung, M. R., Siris, E. S., Eastell, R., Reid, I. R., Delmas, P., Zoog, H. B., Austin, M., Wang, A., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0809493 · Cited by 3,489 · cited 1×
“by about 40 %, and nonvertebral fractures by about 20 % over 3 years [56].”
BackgroundDecreased bioavailability of vitamin D in obesity
Wortsman, J., Matsuoka, L. Y., Chen, T. C., Lu, Z., & Holick, M. F. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/72.3.690 · Cited by 3,204 · cited 1×
“This regimen should be followed by maintenance therapy of 1500–2000 IU/day or whatever dose is needed to maintain the target blood level [37, 38].”
Background
Research works printed but not linked: 4
- Office of the Surgeon General (US) (2004) Bone health and osteoporosis: a report of the Surgeon General. Office of the Surgeon General (US), Rockville (MD). Available from: http://www.ncbi.nlm.nih.gov/books/NBK45513/. Accessed March 2014 20945569
- National Osteoporosis Foundation Physician’s guide to prevention and treatment of osteoporosis 2005 Washington, DC National Osteoporosis Foundation
- Institute of Medicine (US) Committee to review dietary reference intakes for vitamin D and calcium (2011). In: Ross AC, Taylor CL, Yaktine AL et al (eds) Dietary reference intakes for calcium and vitamin D. National Academies Press (US), Washington (DC). Available from: http://www.ncbi.nlm.nih.gov/books/NBK56070/. Accessed March 2014 21796828
- Cummings, SR, San Martin J, McClung MR et al (2009) FREEDOM Trial. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361(8):756–765. (Erratum in: N Engl J Med. 2009;36(10):191) 19671655 · DOI · Paper page
Cited by
Items 2,501–2,600 of 4,108
Zhang, Y., Wang, Z., Lu, M. M., Wang, Q., & Wang, H. (2020) · Medicine · doi:10.1097/md.0000000000019426 · Cited by 6
“Osteoporosis is a skeletal system disorder and the main symptom is bone mineral density reducing, which is an important cause of bone fractures and even a cause to threaten to the lives in elderly people.([2]) Approximately 200 million people with osteoporosis all over the worldand8.”
BackgroundZhang, Y., & Wang, Y. (2020) · The journal of nutrition health & aging · doi:10.1007/s12603-020-1362-z · Cited by 4
Kotlarczyk, M. P., Perera, S., Resnick, N. M., et al. (2020) · Archives of Osteoporosis · doi:10.1007/s11657-020-00749-w · Cited by 4
de Molon, R. S., Fiori, L. C., Verzola, M. H. A., Belluci, M. M., Faloni, A. P. D. S., Pereira, R. M. R., Tetradis, S., & Orrico, S. R. P. (2020) · Archives of Oral Biology · doi:10.1016/j.archoralbio.2020.104779 · Cited by 4
Khalid, M., Khan, F., Baik, M., & Fazal, J. (2020) · Journal of Musculoskeletal Surgery and Research · doi:10.4103/jmsr.jmsr_31_20 · Cited by 4
Bone mineral density in Nigerian men on androgen deprivation therapy for advanced prostate cancer
Ojewuyi, O. O., Ikuerowo, S. O., Jeje, E. A., et al. (2020) · African Journal of Urology · doi:10.1186/s12301-020-00036-7 · Cited by 4
“Studies have shown that results obtained with the use of peripheral accuDEXA can be used to diagnose osteopenia/osteoporosis when DEXA assessment of the hip is not available [33].”
BackgroundIzzy, M. J., Addissie, B. D., Arab, J. P., Hilscher, M. B., Cartee, A. K., Lee, D. C., Lee, Y., Fletcher, J. G., Keaveny, T. M., & Sánchez, W. (2020) · Liver Transplantation · doi:10.1002/lt.25926 · Cited by 4
“(9) Dual-energy X-ray absorptiometry (DXA) is currently the standard test used to diagnose osteoporosis.(10) Despite its widespread use, there are several limitations to DXA, including only modest sensitivity in predicting fracture risk.”
BackgroundRudenka, A., Rudenka, E., Samokhovec, V., Kobets, K., & Marozik, P. M. (2020) · Proceedings of the National Academy of Sciences of Belarus Medical series · doi:10.29235/1814-6023-2020-17-4-480-492 · Cited by 5
Roberts, S., Formanek, B. G., Buser, Z., et al. (2021) · European Spine Journal · doi:10.1007/s00586-020-06706-y · Cited by 4
Yao, S. (2021) · Frontiers in Medical Science Research · doi:10.25236/fmsr.2021.030106 · Cited by 6
Chronic ethanol consumption does not reduce true bone density in male Wistar rats
Clayton, Z. S., Hauffe, L., Liu, C., et al. (2021) · Alcohol · doi:10.1016/j.alcohol.2021.02.003 · Cited by 4
Pérez, S. C., Herrera, L. E., & González, E. (2021) · Climacteric · doi:10.1080/13697137.2021.1918079 · Cited by 5
“The reference range recommended by the International Osteoporosis Foundation (IOF), the International Society for Clinical Densitometry (ISCD) [2], the World Health Organization (WHO) [3], the National Osteoporosis Foundation (NOF) [4] and the American Association of Clinical Endocrinologists (AACE) [5] for calculatin…”
BackgroundBareli, N., Gat, R., Makarov, V., Siris, E. S., Fraenkel, M., & Yoel, U. (2021) · Archives of Osteoporosis · doi:10.1007/s11657-021-00944-3 · Cited by 4
Wopat, M., Breslow, R. M., Chesney, K., McCauley, M., Gysel, R. V., Gray, A., Hilsenhoff, J., Edwardson, G., Nachreiner, J., Hoff, L., et al. (2021) · Journal of the American Pharmacists Association · doi:10.1016/j.japh.2021.07.011 · Cited by 4
Ukrainian FRAX version in the male osteoporosis management
Povoroznyuk, V. V., Johansson, H., Grygorieva, N. V., Kanis, J. А., Musiіenko, А. S., Lorentzon, M., Harvey, N. C., McCloskey, E. V., & Liu, E. (2021) · PAIN JOINTS SPINE · doi:10.22141/2224-1507.11.2.2021.236563 · Cited by 4
FRAX-based intervention thresholds for Pakistan
Johansson, H., Naureen, G., Iqbal, R., et al. (2021) · Osteoporosis International · doi:10.1007/s00198-021-06087-y · Cited by 4
Moffatt, E. K., Wargo, R., Johnson, C., & Kawaguchi‐Suzuki, M. (2021) · JACCP JOURNAL OF THE AMERICAN COLLEGE OF CLINICAL PHARMACY · doi:10.1002/jac5.1544 · Cited by 4
Quality of Life in Women over 65 Years of Age Diagnosed with Osteoporosis
Pastor-Robles, M. B., Mayo-Íscar, A., García, R. M. C., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19095745 · Cited by 4
Presenting Turkish Inappropriate Medication Use in the Elderly (TIME) Criteria Set in Turkish
Bahat, G., İlhan, B., Erdoğan, T., Halil, M. G., Savaş, S., Ülger, Z., Akyüz, F., Bilge, A. K., Çakır, S., Demirkan, K., et al. (2021) · European Journal of Geriatrics and Gerontology · doi:10.4274/ejgg.galenos.2021.6-6 · Cited by 5
Kwok, K., Olatunbosun, C., Ready, E., Sin, O., Toy, J., Spears, A., Lau, V., Bondy, G., & Stone, S. (2022) · The Canadian Journal of Hospital Pharmacy · doi:10.4212/cjhp.3144 · Cited by 6
Kydonaki, E. K., Freitas, L., Reguengo, H., Simón, C. R., Bastos, A. R., Fernandes, E. M., Canadas, R. F., Oliveira, J. M., Correlo, V. M., Reis, R. L., et al. (2022) · Nutrients · doi:10.3390/nu14142837 · Cited by 4
Uzquiano, J. C., Méndez, A. A., Bielsa, Á. J., Carmena, M. D. G., Delgado, J. F., & Sanz-Ayan, P. (2022) · Transplantation Reports · doi:10.1016/j.tpr.2022.100103 · Cited by 4
Li, M. (2022) · Risk Management and Healthcare Policy · doi:10.2147/rmhp.s387506 · Cited by 4
“5 standard deviation (SD) of a measured total BMD using the World Health Organization criteria.(26)”
MethodMohammadi, S. M., Moniri, S., Mohammadhoseini, P., Hanafi, M. G., Farasat, M., & Cheki, M. (2023) · Current Radiopharmaceuticals · doi:10.2174/1874471016666230321120941 · Cited by 5
Sheng‐Kai, K., Chin, N.-C., Tu, T.-Y., Wu, Y., Yip, H., Wei, J. C., & Chang, R. (2023) · Viruses · doi:10.3390/v15041021 · Cited by 4
“To eliminate potential bias, factors including the demographic variables and relevant co-morbidities including hypertension, diabetes mellitus, hyperlipidemia, rheumatoid arthritis, chronic obstructive pulmonary disease (COPD), alcohol-related illness, chronic kidney disease (CKD), inflammatory bowel disease (IBD), HB…”
BackgroundXiao, X., & Wu, Q. F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286689 · Cited by 5
Assessment of Quality of life (QoL) in postmenopausal osteoporosis in the Lublin region
Drozd, M., Szkultecka-Dębek, M., Bułaś, L., et al. (2016) · Journal of Health Policy & Outcomes Research · doi:10.7365/jhpor.2016.1.11 · Cited by 4
Komrakova, M., Schilling, A. F., Lehmann, W., Vasilev, V., Georgieva, K. N., Gerginska, F., Boyadjiev, N., & Delchev, S. (2023) · Pharmaceuticals · doi:10.3390/ph16091249 · Cited by 5
“Physical activity is therefore recommended as a proven means for osteoporosis prevention and rehabilitation [3], as exercise interventions during childhood and adulthood are supposed to mitigate age-related bone loss [1].”
BackgroundChen, X.-X., Tian, C.-W., Bai, L., Zhao, Y.-K., Zhang, C., Shi, L., Zhang, Y., Xie, W.-J., Zhu, H.-Y., Chen, H., et al. (2023) · World Journal of Orthopedics · doi:10.5312/wjo.v14.i9.720 · Cited by 4
Alghamdi, A., Almutairi, O. A., Alqam, R. A., et al. (2023) · Cureus · doi:10.7759/cureus.45191 · Cited by 4
“While osteoporosis cannot be cured, it can be prevented by quitting smoking, drinking less alcohol, eating enough calcium and vitamin D, avoiding falls, and increasing physical activity overall at all ages [4].”
BackgroundThe incremental risk of fragility fractures in aging men
Agarwal, A. R., Tarawneh, O. H., Cohen, J. S., Gu, A., Moseley, K. F., DeBritz, J., Golladay, G. J., & Thakkar, S. C. (2023) · Osteoporosis International · doi:10.1007/s00198-023-06956-8 · Cited by 4
“The National Osteoporosis Foundation, the American Academy of Family Physicians, and the Endocrine Society each recommend screening men at the age of 70 [14, 43].”
Correlation study between bone metabolic markers, bone mineral density, and sarcopenia
Xie, W., He, M., Yu, D. J., Li, H., Jin, H. F., Ji, B., Yang, G., Chen, L., Rahmati, M., & Li, Y. S. (2023) · Journal of Endocrinological Investigation · doi:10.1007/s40618-023-02252-8 · Cited by 5
Kopiczko, A. (2024) · Biomedical Human Kinetics · doi:10.2478/bhk-2024-0001 · Cited by 4
Utilization and Reporting of Bone Densitometry
Ruutiainen, A. T. (2015) · Academic Radiology · doi:10.1016/j.acra.2015.02.008 · Cited by 4
Dual X-ray Absorptiometry for Diagnosis of Osteoporosis
Neuner, J. M., & Carnahan, J. (2014) · JAMA · doi:10.1001/jama.2014.1402 · Cited by 4
Clinical Vignettes: Using Non-BMD Measurements in Clinical Practice
Lewiecki, E. M. (2015) · Clinical Reviews in Bone and Mineral Metabolism · doi:10.1007/s12018-015-9200-2 · Cited by 4
Self-citationCommunity Pharmacist-Provided Osteoporosis Screening and Education: Impact on Patient Knowledge
Brookhart, A. L., Fountain, K., Moczygemba, L. R., & Goode, J. R. (2015) · INNOVATIONS in pharmacy · doi:10.24926/iip.v6i3.395 · Cited by 5
Vanaky, B., Sadeghi, H., & Ramezani, N. (2014) · Biosciences Biotechnology Research Asia · doi:10.13005/bbra/1361 · Cited by 4
Preventive Care in Women’s Health
Blanchard, A. K., & Goodall, P. (2016) · Obstetrics and Gynecology Clinics of North America · doi:10.1016/j.ogc.2016.01.008 · Cited by 4
Batur, P., Rice, S., Barrios, P. A., & Sikon, A. L. (2017) · Journal of Women s Health · doi:10.1089/jwh.2017.6496 · Cited by 5
Mandibular Cortical Width on Panoramic Images of Children in the Lao People’s Democratic Republic
Vongsa, S., Aboshi, H., Ejima, K.-I., et al. (2018) · Journal of Hard Tissue Biology · doi:10.2485/jhtb.27.23 · Cited by 4
Türk, A. Ç., Şahin, F., Küçükler, F. K., et al. (2018) · Saudi Medical Journal · doi:10.15537/smj.2018.7.22580 · Cited by 4
Casas-Ávila, L., de León-Suárez, V. P., Peñaloza‐Espinosa, R. I., Cerda-Flores, R. M., Pérez-Ríos, A., Martínez‐Ramírez, O. C., Rubio-Lightbourn, J., Hernández, C. C., & Valdés‐Flores, M. (2018) · Gynecological Endocrinology · doi:10.1080/09513590.2018.1481943 · Cited by 4
Preventive Effects of Physical Activity in Older People
Strandberg, T. E. (2019) · Cambridge University Press eBooks · doi:10.1017/9781316677018.012 · Cited by 9
Inderjeeth, C. A., & Raymond, W. D. (2019) · Archives of Gerontology and Geriatrics · doi:10.1016/j.archger.2019.103940 · Cited by 4
Suzuki, T., Nakamura, Y., & Kato, H. (2019) · Osteoporosis and Sarcopenia · doi:10.1016/j.afos.2019.11.004 · Cited by 4
“Although multiple antiresorptive and bone-forming drugs are available for osteoporosis, this condition remains the most common bone disease in humans [1].”
BackgroundLi, G., Leslie, W. D., Kovács, C. S., Prior, J. C., Josse, R. G., Towheed, T., Davison, K. S., Thabane, L., Παπαϊωάννου, Α., Levine, M., et al. (2020) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3971 · Cited by 5
“More adequately powered and well-designed studies are needed to assess the relationship between FI + TBS and fracture risk in specific sites and further clarify the comparative predictive power between FI + TBS, FIalone, and TBS-alonemodels.”
BackgroundMethodInfluentialFang, P., Chen, Y., Chen, J.-L., Sun, J., Tan, J., Wang, R., & Wang, X. (2020) · Medicine · doi:10.1097/md.0000000000021811 · Cited by 4
“For example, CPG published by National Osteoporosis Foundation in 2014 recommended BMD testing should be performed in men age 70 and older.([17]) But, US Preventive Services Task Force guidelines issued in 2018 consider that current evidence is insufficient to support screening for osteoporosis in men.”
MethodThe Risk of Osteoporotic Forearm Fractures in Postmenopausal Women in a Siberian Population Sample
Сергеевна, М. Е., Rymar, O. D., Щербакова, Л. В., Викторовна, М. Е., & Malyutina, S. K. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030077 · Cited by 4
“Dual-energy X-ray absorptiometry (DXA) screening is standard in the US (at the age of 65 years in women and age 70 in men, and in individuals over the age of 50 years who have suffered an adult fracture) [13], but, in the majority of other countries, population screening is not judged to be cost-effective and primary…”
BackgroundProphylaxis of Pain and Fractures within Feet in the Course of Osteoporosis: The Issue of Diagnosing
Bitenc-Jasiejko, A., Konior, K., Gonta, K., Dulęba, M., & Lietz–Kijak, D. (2020) · Pain Research and Management · doi:10.1155/2020/1391026 · Cited by 5
de Melo, J. A. C., da Silva, C., Alves, M. L. D. S., et al. (2020) · Saberes Plurais Educação na Saúde · doi:10.54909/sp.v4i2.108759 · Cited by 4
Vazquez-Villegas, M. L., Rodriguez-Jimenez, N. A., Contreras-Haro, B., Vásquez-Jiménez, J. C., Pérez-Guerrero, E. E., Morán-Moguel, M. C., Sánchez-Rodríguez, E. N., Alejandra, V.-V., Nuño‐Arana, I., Becerra-Alvarado, I. N., et al. (2021) · Genetic Testing and Molecular Biomarkers · doi:10.1089/gtmb.2020.0199 · Cited by 4
“O steoporosis (OP) is characterized by loss of bone mineral mass, leading to a deterioration of the bone microarchitecture and an increased risk of bone fractures (Cosman et al. , 2014).”
How to implement guidelines and models of care
Geusens, P., Appelman‐Dijkstra, N. M., Zillikens, M. C., Willems, H. C., Lems, W. F., & van den Bergh, J. P. (2022) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2022.101759 · Cited by 4
Cystic fibrosis: A clinician's tool for management of care advancing into the adult population
Nast, D., Paniagua, C., & ANDERSON, P. J. (2012) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2012.00763.x · Cited by 4
Calcium Primer: Current Controversies and Common Clinical Questions
McDaniel, M. H., & Williams, S. E. (2013) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2013.08.009 · Cited by 4
Zhao, Y. W., Johnston, S. S., Smith, D. M., McMorrow, D., Krohn, K., & Krege, J. H. (2013) · Osteoporosis International · doi:10.1007/s00198-013-2324-7 · Cited by 5
O’Brien, L. K., Armstrong, A. D., Hassenbein, S. E., et al. (2015) · Geriatric Orthopaedic Surgery & Rehabilitation · doi:10.1177/2151458515604359 · Cited by 4
Park, J.-S., Lee, J., & Park, Y. (2016) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2015.12.003 · Cited by 4
Physical Functioning Among Women Aged 80 Years and Older With Previous Fracture
Crandall, C. J., LaMonte, M. J., Snively, B. M., LeBoff, M. S., Cauley, J. A., Lewis, C. E., Wallace, R. B., Li, W., Chen, Z., Robbins, J. A., et al. (2016) · The Journals of Gerontology Series A · doi:10.1093/gerona/glv060 · Cited by 4
Self-citationClinical Use of Bone Densitometry
Bonnick, S. L., & Miller, P. D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00066-2 · Cited by 4
Effect of Moringa Oleifera on Bone Density in Post‐Menopausal Women
Brown, J., Merritt, E., Mowa, C. N., & McAnulty, S. R. (2016) · The FASEB Journal · doi:10.1096/fasebj.30.1_supplement.678.21 · Cited by 4
A reprodukciós öregedés és a csontszerkezet változásának kapcsolata nőknél
Zsákai, A., & Bodzsar, E. B. (2016) · Anthropologiai Közlemények · doi:10.20330/anthropkozl.2016.57.77 · Cited by 4
Osteoporosis and the Role of Physical Therapy in the Different Domains
Pósa, G., Róka, E., Szíver, E., Finta, R., Szilágyi, L., Koncsek, K., & Nagy, E. (2017) · Journal of Osteoporosis and Physical Activity · doi:10.4172/2329-9509.1000190 · Cited by 4
Csontanyagcsere felnőtt phenylketonuriás pácienseknél – hazai adatok
Barta, A. G., Sumánszki, C., & Reismann, P. (2017) · Orvosi Hetilap · doi:10.1556/650.2017.30889 · Cited by 4
Osteonecrosis of the Jaw and Atypical Femoral Fractures
Shane, E. J., Khosla, S., & Burr, D. (2013) · Elsevier eBooks · doi:10.1016/b978-0-12-415853-5.00081-9 · Cited by 5
Recent advances and current trend in the pharmacotherapy of postmenopausal osteoporosis
Fasipe, O. J., Ibiyemi-Fasipe, O., Adelosoye, A., & Idowu, A. (2018) · Journal of Health Research and Reviews · doi:10.4103/jhrr.jhrr_104_17 · Cited by 4
Factors Influencing Nutrition Label Reading Behavior in Individuals With Selected Chronic Diseases
Rose, T. M., Unni, E., & Jones, G. J. (2018) · American Journal of Health Education · doi:10.1080/19325037.2018.1486756 · Cited by 6
Sale, J. E. M., Gray, M., Mancuso, D., Inrig, T., Boire, G., Beaulieu, M., Funnell, L., & Bogoch, E. R. (2018) · Rheumatology International · doi:10.1007/s00296-018-4181-3 · Cited by 5
Kaya, B., Ates, E., Paydaş, S., Sertdemır, Y., & Balal, M. (2019) · Transplantation Proceedings · doi:10.1016/j.transproceed.2019.03.048 · Cited by 4
Xu, Z., Wang, H., Shi, Y., Shen, Q., Tsamlag, L., Wang, Z., Yu, S., Tian, S., Wang, Y., & Cai, Y. (2019) · British Journal Of Nutrition · doi:10.1017/s0007114519002290 · Cited by 5
Cholecalciferol and calcifediol for vitamin D supplementation
Henríquez, M. S. (2019) · Osteoporosis International · doi:10.1007/s00198-019-05163-8 · Cited by 4
Jameshouran, M. A. G., Abedi, A. R., Montazeri, S., Tasharrofi, M. A., & Tehrani, M. M. M. (2020) · Iranian Journal of Radiology · doi:10.5812/iranjradiol.102177 · Cited by 4
“5), using the lowest reported T-score at any given location, according to previously established guidelines (8, 24-27).”
MethodClinical Implementation of Bone Regeneration and Maintenance
Barbeck, M., Rosenberg, N., Kačarević, Ž. P., Jung, O., & Rider, P. (2019) · IntechOpen eBooks · doi:10.5772/intechopen.85328 · Cited by 4
Yano, T., Ito, T., Kanehira, Y., et al. (2021) · Bone Reports · doi:10.1016/j.bonr.2021.101061 · Cited by 4
Rethinking of osteoporosis through a sex- and gender-informed approach in the COVID-19 era
VIOLI, A., FORTUNATO, V., D’Amuri, A., Zuliani, G., Basili, S., Passaro, A., Corica, B., & Raparelli, V. (2021) · Minerva Obstetrics and Gynecology · doi:10.23736/s2724-606x.21.04893-4 · Cited by 6
Sciamanna, C., Ballentine, N. H., Bopp, M., Chinchilli, V. M., Ciccolo, J. T., Delauter, G., Fisher, A., Fox, E. J., de Beur, S. M. J., Kearcher, K., et al. (2021) · Trials · doi:10.1186/s13063-021-05761-0 · Cited by 6
Self-citationKhanna, V. (2017) · Juniper Online Journal of Case Studies · doi:10.19080/jojcs.2017.01.555570 · Cited by 5
Alkhateeb, S., Abusamra, A. J., Murshid, E., Kushi, H., Al-Mansour, M. M., Saadeddin, A., Rabah, D. M., Bazarbashi, S. N., Alotaibi, M., Alghamdi, A. M., et al. (2016) · Urology Annals · doi:10.4103/0974-7796.176872 · Cited by 4
Akinpetide, G. O. (2014) · UA Campus Repository (The University of Arizona) · Cited by 4
Calcium, Magnesium, and Vitamin D Absorption; Metabolim and Deficiency
Civitelli, R., Ziambaras, K., & Ward, W. E. (2018) · Encyclopedia of Gastroenterology · doi:10.1016/b978-0-12-801238-3.66113-5 · Cited by 4
Ibrahim, M. O., Kolleri, A., & Ginawi, A. (2023) · International Journal of Rheumatology · doi:10.1155/2023/2160346 · Cited by 5
“On the other hand, the National Osteoporosis Foundation (NOF) recommends that BMD testing be repeated one to two years after starting treatment and every two years, with more repeated testing in certain clinical conditions [17].”
BackgroundMethodInfluentialKhoroushi, F., Keykhosravi, E., Shakeri, M. T., Salari, M., Hassannejad, E., Payandeh, A., & Salarzaei, O. (2024) · Egyptian Rheumatology and Rehabilitation · doi:10.1186/s43166-024-00253-w · Cited by 8
“According to the report from the World Health Organization (WHO), BMD is categorized as normal when the T -score is within ± 1SD, osteopenia when the T -score ranges between − 1.0 and − 2.5 SD, and osteoporosis when the T -score falls below − 2.5 SD [6].”
MethodInfluentialDurmuşlar, M. C., Gülşen, E. A., Bayburt, K. A., et al. (2024) · Saudi Medical Journal · doi:10.15537/smj.2024.45.8.20240224 · Cited by 3
Cheneymann, A., Therkildsen, J., Rasmussen, L., Thygesen, J., Isaksen, C., Hauge, E., Winther, S., & Bøttcher, M. (2024) · Calcified Tissue International · doi:10.1007/s00223-024-01268-3 · Cited by 3
Fodeh, S. J., Wang, R., Murphy, T. E., Kidwai‐Khan, F., Leo-Summers, L. S., Tessier‐Sherman, B., Hsieh, E., & Womack, J. A. (2024) · Health Informatics Journal · doi:10.1177/14604582241295930 · Cited by 5
Emir, S. N., & Güner, G. (2025) · Journal of Clinical Densitometry · doi:10.1016/j.jocd.2025.101561 · Cited by 3
Troian-Michel, C. H., Só, B. B., Schuch, L. F., Stelter, G. O., Schmidt, T. R., Schorr, J. L., Campagnol, D., Garcez, T. N. A., Só, G. B., Arrué, T. A., et al. (2025) · International Endodontic Journal · doi:10.1111/iej.14234 · Cited by 4
“It is the most common bone disease in humans, characterized by reduced mass, tissue deterioration and disruption of bone architecture, compromising strength and increasing the risk of fractures (Cosman et al., 2014).”
Liang, J., Xu, J., Cao, Y., Wei, Y.-L., Lin, G.-J., Jin, J., Li, C., & Lü, K. (2025) · Scientific Reports · doi:10.1038/s41598-025-98089-7 · Cited by 5
White, K., Shakir, M. K. M., Nguyen, C., & Hoang, T. D. (2025) · Journal of Medical Case Reports · doi:10.1186/s13256-025-05353-5 · Cited by 3
“Osteopenia has a prevalence of four times greater than osteoporosis for most fractures in this population [2–4].”
Wei, B., Miao, Z., Yang, X., Chen, S., Guo, X., Wang, J., Huang, X. S., Zhang, H., Wang, X., & Jia, B. (2025) · Frontiers in Public Health · doi:10.3389/fpubh.2025.1584610 · Cited by 3
Charchar, H. L. S., Alencar, G. A., Mariani, B. M. P., Kuhn, A. W., Silva, J. T. D. C., Bouys, L., Vaduva, P., Nishi, M. Y., Ledesma, F. L., Almeida, M. Q., et al. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf465 · Cited by 4
Du, Y., Xu, F.-T., Miao, S., Zhou, B., Mo, J., & Liu, Z. (2025) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2025.106866 · Cited by 4
Vitamin D intake in Italian healthy subjects and patients with different pathological disorders
Nuti, R., Gennari, L., Cavati, G., Caffarelli, C., Frediani, B., Gonnelli, S., Laurentaci, C., Mauro, G. L., Malavolta, N., Minisola, G., et al. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1672798 · Cited by 3
“…with extremely low vitamin D levels or osteoporosis: considering seasons/sun-light exposure and dietary vitamin D intakes, in adults > 50 years old and those with a higher bone fracture risk, daily intake of 800–1,000 IU of vitamin D, including supplements if necessary, are recommended (51).”
Investigating the Role of Exercise in Improving Bone Health Among Elderly Women with Osteopenia
Kotsili, K., Michou, V., Κουτλιάνος, Ν., Dalkiranis, A., Kouidi, E. J., & Deligiannis, A. P. (2025) · Journal of Functional Morphology and Kinesiology · doi:10.3390/jfmk10040451 · Cited by 4
“These factors lead to increased bone fragility and a higher risk of fractures [3].”
Jia, P., Yang, Y., Fang, Z., & Tang, X. (2025) · Journal of Orthopaedic Surgery and Research · doi:10.1186/s13018-025-06447-y · Cited by 5
Wadhwa, H., Isakoff, K. J., Segovia, N. A., Goodnough, L. H., Bishop, J. A., & Gardner, M. J. (2026) · Bone · doi:10.1016/j.bone.2026.117835 · Cited by 4
Yan, S., Du, Q., Zhao, L., Liu, Q., Wu, M., Xu, Z., & Shen, J. (2026) · Chinese Medicine · doi:10.1186/s13020-026-01353-9 · Cited by 7
“…medical conditions or medications that adversely affect bone metabolism, mechanistically involving inflammatory cytokines, glucocorticoid-induced suppression of osteoblast activity and promotion of osteoclast survival, hormone deficiencies, or drug-related interference with bone remodeling [4, 5].”
The gut-bone axis: impact of diet on gut microbiome and osteoporosis
Wang, Y., Xu, M., Dong, Q., Lin, X., Zhang, Q., Shi, H., Lin, X., Liu, H., Yu, M., & Shen, J. (2026) · Bone Research · doi:10.1038/s41413-026-00550-4 · Cited by 12
Indications and Outcomes of Osteoporosis and Bone Modulation Therapies
Weinerman, S. A., & Usera, G. L. (2015) · Oral and Maxillofacial Surgery Clinics of North America · doi:10.1016/j.coms.2015.06.009 · Cited by 3
Ramcharan, M., Faillace, M. E., Guengerich, Z., Williams, V. A., & Jepsen, K. J. (2016) · Osteoporosis International · doi:10.1007/s00198-016-3801-6 · Cited by 4
Metadata
- Authors
- Cosman, F., de Beur, S. J., LeBoff, M. S., Lewiecki, E. M., Tanner, B., Randall, S., & Lindsay, R.
- Affiliations
- Helen Hayes Hospital (US)
- Brigham and Women's Hospital (US)
- New Mexico Clinical Research & Osteoporosis Center (US)
- Bone Health and Osteoporosis Foundation (US)
- Corresponding author
- Cosman, F.
- Venue
- Osteoporosis International
- Published
- 2014-08-15
- Volume
- 25
- Issue
- 10
- Pages
- 2359-2381
- ISSN
- 0937-941X (ISSN-L)
- 1433-2965
- PMC
- PMC4176573
- OpenAlex
- W2171709369
- Semantic Scholar
- 91c0d02cdbd4c5dd69ed206e6a0b2b94c9aa0830
- Cited by
- 4,149
- References
- 101
- Citations by year
- 2026: 141 · 2025: 226 · 2024: 267 · 2023: 292 · 2022: 351 · 2021: 415 · 2020: 458 · 2019: 336 · 2018: 311 · 2017: 304 · 2016: 285 · 2015: 246 · 2014: 141
- FWCI
- 242.08
- Type
- journal article
- Language
- en
- Update notices
- correction (2015-05-19)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Osteoporosis International (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- PubMed Central (submittedVersion, cc-by-nc)
- Topics
- Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Health Sciences › Medicine › Surgery › Hip and Femur Fractures
- Keywords
- osteoporosis, osteoporosis prevention, osteoporosis treatment, bone health, osteoporosis drugs
- MeSH terms
- Aged, Calcium, Dietary, Diet, Female, Humans, Male, Middle Aged, Osteoporosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-09-30, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-09-30 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.